Toronto, Oct.17th 2023-Geneseeq Technology Inc. is excited to share four collaborated studies at the 2023 European Society for Medical Oncology (ESMO) annual meeting from October.20th-24th at Madrid, Spain.

Highlights of these studies include:

  • A mini oral presentation on discussing the chronic psychological stress in advanced non-small cell lung cancer (NSCLC) treated with first-line immunotherapy
  • Data on Geneseeq’s cfDNA fragmentomics model to predict the risk of colorectal cancer
  • Two clinical trial studies evaluate the efficacy and safety of new drug combinations in NSCLC and thymic carcinoma


List of abstracts that will be presented at the ESMO 2023 meeting: